Immunotherapy of cancer;Immunterapi af cancersygdomme

Ugeskrift for Laeger

Volumn 164, Issue 23, 2002, Pages 3008-3016

  Andersen, Mads Hald ^a   Schmidt, Henrik ^a   Gehl, Julie ^a   von der Maase, Hans ^a   Straten, Per T ^a  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CISPLATIN; CYTOKINE; DACARBAZINE; EPITOPE; FLUOROURACIL; HLA ANTIGEN; INTERFERON; INTERLEUKIN 2; TUMOR ANTIGEN; VINBLASTINE; ANTINEOPLASTIC AGENT;

ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER THERAPY; CELL INTERACTION; CLINICAL IMMUNOLOGY; CLINICAL STUDY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HOST CELL; HUMAN; IMMUNE SYSTEM; METHODOLOGY; PATIENT CARE; PATIENT MONITORING; TUMOR CELL; TUMOR IMMUNOLOGY; TUMOR REJECTION; ACTIVE IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASM; PASSIVE IMMUNIZATION; REVIEW; T LYMPHOCYTE;

ANTINEOPLASTIC AGENTS; CANCER VACCINES; COMBINED MODALITY THERAPY; CYTOKINES; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOTHERAPY; IMMUNOTHERAPY, ACTIVE; NEOPLASMS; T-LYMPHOCYTES;

EID: 0037013394     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Design and evaluation of antigen-specific vaccination strategies against cancer
2. The treatment of malignant tumors by repeated inoculations of erysipelas
3. The concept of immunological surveillance
4. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma
5. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy
6. Peptides bound to major histocompatibility complex molecules
7. A listing of human tumor antigens recognized by Tcells
8. T-cell recognition of melanoma antigens and its therapeutic applications
9. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes
10. Identification of a cytotoxic T lymphocyte response to the apoptose inhibitor protein survivin in cancer patients
11. Spontaneous cytotoxic T-cell responses against survivin derived MHC class I restricted T-cell epitopes in situ as well as ex vivo in cancer patients
12. Induction of apoptosis and inhibition of cell proliferation by survivin gene targeting
13. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients
14. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
15. Treatment of metastatic renal cell carcinoma by continuous intravenous infusion of recombinant interleukin-2: A single-center phase II study
16. Disseminated malignant melanoma and recombinant interferon: Analysis of seven consecutive phase II investigations
17. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2
18. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993
19. Salpetriere Hospital experience with biochemotherapy in metastatic melanoma
20. Interferon alpha-2a and interleukin-2 with or without cisplatin in metastatic melanoma: A randomized trial of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group
21. Subcutaneous interleukin-2 and interferon-alpha plus cisplatin with and without prophylactic cimetidine in patients with metastatic malignant melanoma: A phase II study
22. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma
23. Interferon alfa-2a in advanced renal cell carcinoma: Treatment results and survival in 159 patients with long-term follow-up
24. Recombinant interleukin-2 in metastatic renal cell carcinoma - A European multicentre phase II study
25. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma
26. Interleukin-2 based home therapy of metastatic renal cell carcinoma: Risks and benefits in 215 consecutive single institution patients
27. Outpatient treatment with subcutaneous histamine dihydrochloride in combination with interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma: Results of an open, single-armed, multi-center phase-II study
28. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response
29. Long-term follow-up of patients with metastatic renal cell carcinoma treated with intravenous recombinant interleukin-2 in Europe
30. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
31. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the gm2-klh/qs-21 vaccine in patients with resected stage iib-iii melanoma: Results of intergroup trial e1694/s9512/c509801
32. High- and low-dose interferon a1fa-2b in high-risk melanoma: First analysis of intergroup trial E1690/S9111/C9190
33. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: A Federation Nationale des Centres de Lutte Contre parallel study
34. Low-dose integrated chemoimmuno-hormonotherapy with cisplatin, subcutaneous interleukin-2, alpha-interferon and tamoxifen for advanced metastatic melanoma - A pilot study
35. Histamine: A novel approach to cancer immunotherapy
36. Vaccination against human cancers
37. Vaccination with IL-7 gene-modified autologous melanoma cells can enhance the anti-melanoma lytic activity in peripheral blood of patients with a good clinical performance status: A clinical phase I study
38. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study
39. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
40. Overview analysis of adjuvant therapies for melanoma - A special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials
41. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
42. Heat shock proteins: The "Swiss Army Knife" vaccines against cancers and infectious agents
43. CD91: A receptor for heat shock protein gp96
44. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations
45. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3
46. Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: Implications for tumor vaccines with melanoma-associated antigens
47. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
48. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
49. Immunotherapy for prostate cancer
50. Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Association between disease progression and cessation of CTL responses
51. Escape from host-antitumor immunity
52. Treatment of patients with metastatic melanoma with autologous tumor- infiltrating lymphocytes and interleukin 2
53. Tumor infiltrating lymphocytes in melanoma comprise high numbers of T-cell clonotypes that are losturing in vitro culture
54. Strategies for immunotherapy of cancer
55. Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T-cells in stage IV melanoma patients